Stemline Therapeutics (NASDAQ:STML) Announces Quarterly Earnings Results, Beats Estimates By $0.08 EPS

Stemline Therapeutics (NASDAQ:STML) announced its earnings results on Thursday. The biopharmaceutical company reported ($0.34) EPS for the quarter, topping the consensus estimate of ($0.42) by $0.08, Fidelity Earnings reports. The firm had revenue of $13.33 million during the quarter, compared to the consensus estimate of $13.40 million.

NASDAQ STML traded down $1.19 during midday trading on Friday, hitting $9.25. The company had a trading volume of 2,655,100 shares, compared to its average volume of 625,907. Stemline Therapeutics has a fifty-two week low of $7.82 and a fifty-two week high of $18.22. The stock has a market cap of $486.37 million, a price-to-earnings ratio of -3.09 and a beta of 1.35. The company has a quick ratio of 4.57, a current ratio of 4.71 and a debt-to-equity ratio of 0.01. The firm has a fifty day simple moving average of $9.85 and a two-hundred day simple moving average of $12.94.

Several research analysts recently commented on STML shares. Zacks Investment Research downgraded shares of Stemline Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, October 30th. Wedbush upgraded shares of Stemline Therapeutics from a “neutral” rating to an “outperform” rating in a report on Friday, August 2nd. HC Wainwright reiterated a “buy” rating and issued a $35.00 target price on shares of Stemline Therapeutics in a report on Monday, September 30th. Cowen reiterated a “buy” rating on shares of Stemline Therapeutics in a report on Wednesday, September 18th. Finally, ValuEngine downgraded shares of Stemline Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, September 11th. Three research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Stemline Therapeutics currently has an average rating of “Buy” and a consensus price target of $22.83.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

In other Stemline Therapeutics news, CEO Ivan Bergstein sold 35,010 shares of the business’s stock in a transaction dated Wednesday, August 14th. The shares were sold at an average price of $14.73, for a total value of $515,697.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 13.10% of the company’s stock.

About Stemline Therapeutics

Stemline Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of oncology therapeutics in the United States and internationally. The company offers ELZONRIS, a targeted therapy directed to the interleukin-3 receptor (CD123) for patients with blastic plasmacytoid dendritic cell neoplasm in adults, and in pediatric patients two years and older.

Featured Story: What is quantitative easing?

Earnings History for Stemline Therapeutics (NASDAQ:STML)

Leave a Reply

Your email address will not be published. Required fields are marked *

*